The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
Gynecological Cancer Targets
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.
A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients
Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.
Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.